EUCTR2004-001287-49-ES进行中（未招募）1 期
52-week, open, randomized, multinational, multicenter clinical trial comparing insulin glulisine in combination with insulin glargine in an intensified insulin regimen to a two-injection conventional insulin regimen in type 2 diabetes mellitus patients with poor glycemic control pretreated with a two-injection conventional insulin therapy. - GINGER-Study
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 372
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Type 2 diabetes mellitus, as defined by the American Diabetes Association for at least five years, treated with insulin for at least one year (no history of ketoacidosis).
- •2.Men or women aged 18 to 70 years old, inclusive.
- •3.Pre-screening HbA1c between 8.0% and 11.0%, inclusive and not more than 0.5 % HbA1c-improvement at pre-randomization (week -2).
- •4.For at least 3 months prior to week –8 visit, subjects must have been on a stable insulin regimen with two daily s.c. injections of premixed insulin: NPH plus regular insulin or NPH plus rapid acting insulin (insulin lispro or insulin aspart) in a mixture of 70/30 or 75/25. Stable” means no change in regimen and no more than 30 % change in dose. Optionally, the subject can have been treated in addition with metformin according to its current official product information leaflet, treatment with other oral blood glucose lowering drugs is not allowed.
- •5.Documentation of a full ophthalmologic exam (incl. fundoscopy), by an ophthalmologist, during the 6 months prior to randomization. For exclusion criteria refer to exclusion criterion 7.
- •6.Women are either not of childbearing potential (surgically sterile, or postmenopausal for more than 2 years). Women of childbearing potential must not be pregnant and agree to use a reliable contraceptive measure for the duration of the study. Reliable contraceptive measures include the following: systemic contraceptive (oral, implant, injections), diaphragm with intravaginal spermicide, cervical cap, intrauterine device or condom with spermicide.
- •Are the trial subjects under 18?
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Two or more severe hypoglycemic episodes within the past 3 months, or any hospitalization or emergency room visit due to poor diabetic control within the past 3 months prior to randomization.
- •2.History of hypoglycemia unawareness.
- •3.Impaired hepatic function, as shown by, but not limited to, ALAT (SGPT) or ASAT (SGOT) above 2x the upper limit of normal as measured at visit 1.
- •4.Impaired renal function, as shown by, but not limited to, serum creatinine > 177 mmol/l (> 2 mg/dl) as measured at visit 1 (if no lower values due to individual metformin intake are required) or current renal dialysis.
- •5.Body mass index (BMI) > 32 kg/m2.
- •6.Any other clinically significant abnormalities on screening laboratory evaluation (unless discussed with the monitor and approved by the study management).
- •7.Active proliferative diabetic retinopathy, as defined by the application of focal or panretinal photocoagulation or vitrectomy, in the 6 months prior to visit 1, or any other unstable (rapidly progressing) retinopathy that may require surgical treatment (including laser photocoagulation) during the study.
- •8.History of hypersensitivity to insulin or insulin analogues or any of the excipients in the HMR 1964 formulation.
- •9.Donation of blood or transfusion during the 2 months prior to the screening visit.
- •10.Pregnant or lactating women, or women planning to become pregnant during the study.
- •11.Treatment with any investigational drug in the last month before visit 1 (screening).
研究者
相似试验
进行中（未招募）
1 期
52-week, open, randomized, multinational, multicenter clinical trial comparing insulin glulisine in combination with insulin glargine in an intensified insulin regimen to a two-injection conventional insulin regimen in type 2 diabetes mellitus patients with poor glycemic control pretreated with a two-injection conventional insulin therapy - GINGER-StudyDiabetes mellitus type 2Classification code 10012613EUCTR2004-001287-49-SKSanofi Aventis Deutschland GmbH372
进行中（未招募）
1 期
52-week, open, randomized, multinational, multicenter clinical trial comparing insulin glulisine in combination with insulin glargine in an intensified insulin regimen to a two-injection conventional insulin regimen in type 2 diabetes mellitus patients with poor glycemic control pretreated with a two-injection conventional insulin therapy - GINGER-StudyDiabetes mellitus type 2Classification code 10012613EUCTR2004-001287-49-GBSanofi-Aventis Deutschland GmbH268
进行中（未招募）
不适用
52-week, open, randomized, multinational, multicenter clinical trial comparing insulin glulisine in combination with insulin glargine in an intensified insulin regimen to a two-injection conventional insulin regimen in type 2 diabetes mellitus patients with poor glycemic control pretreated with a two-injection conventional insulin therapy - GINGER-StudyDiabetes mellitus type 2Classification code 10012613EUCTR2004-001287-49-SESanofi-Aventis Deutschland GmbH268
进行中（未招募）
不适用
52-week, open, randomized, multinational, multicenter clinical trial comparing insulin glulisine in combination with insulin glargine in an intensified insulin regimen to a two-injection conventional insulin regimen in type 2 diabetes mellitus patients with poor glycemic control pretreated with a two-injection conventional insulin therapyType 2 diabetes mellitusMedDRA version: 9.1Level: HLTClassification code 10012602Term: Diabetes mellitus (incl subtypes)EUCTR2004-001287-49-ITAVENTIS PHARMA S.P.A.372
已完成
不适用
Comprehensive Rimonabant Evaluation Study of Cardiovascular ENDpoints and Outcomes-E669 Obesity, unspecifiedObesity, unspecifiedE669PER-053-08sanofi-aventis Recherche & Development,